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Abstract
PTEN, a phosphoinositide-3-phosphatase, serves dual roles as a tumor suppressor and regulator of cellular anabolic/
catabolic metabolism. Adaptation of a redox-sensitive cysteinyl thiol in PTEN for signal transduction by hydrogen peroxide
may have superimposed a vulnerability to other mediators of oxidative stress and inflammation, especially reactive carbonyl
species, which are commonly occurring by-products of arachidonic acid peroxidation. Using MCF7 and HEK-293 cells, we
report that several reactive aldehydes and ketones, e.g. electrophilic a,b-enals (acrolein, 4-hydroxy-2-nonenal) and a,b-
enones (prostaglandin A2, D12-prostaglandin J2 and 15-deoxy-D-12,14-prostaglandin J2) covalently modify and inactivate
cellular PTEN, with ensuing activation of PKB/Akt kinase; phosphorylation of Akt substrates; increased cell proliferation; and
increased nuclear b-catenin signaling. Alkylation of PTEN by a,b-enals/enones and interference with its restraint of cellular
PKB/Akt signaling may accentuate hyperplastic and neoplastic disorders associated with chronic inflammation, oxidative
stress, or aging.
Citation: Covey TM, Edes K, Coombs GS, Virshup DM, Fitzpatrick FA (2010) Alkylation of the Tumor Suppressor PTEN Activates Akt and b-Catenin Signaling: A
Mechanism Linking Inflammation and Oxidative Stress with Cancer. PLoS ONE 5(10): e13545. doi:10.1371/journal.pone.0013545
Editor: Marcelo G. Bonini, University of Illinois at Chicago, United States of America
Received July 8, 2010; Accepted August 30, 2010; Published October 21, 2010
Copyright:  2010 Covey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by the National Institutes of Health Research Project Grant R01 AI 26730 (Frank A. Fitzpatrick), Research Program Projects PO1
CA73992 Project 4 (David M. Virshup) and Project 5 (Frank A. Fitzpatrick), and Small Grant Program R03 MH082387-01 (Gary S. Coombs, David M. Virshup and
Frank A. Fitzpatrick). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: FFitzpatrick@kcumb.edu
¤a Current address: Program in Cancer and Stem Cell Biology, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore
¤b Current address: Kansas City University of Medicine and Biosciences, Kansas City, Missouri, United States of America
Introduction
Inflammation and cancer are intricately linked [1,2]. ‘Smolder-
ing’ inflammation [3], also called para-inflammation [4], occurs in
many types of pre-malignant and malignant tumors, e.g. colorectal
adenoma and adenocarcinoma where the content of inflammatory
leukocytes and the inflammatory enzyme cyclooxygenase-2 (COX-
2) influence progression, prognosis and survival [5,6]. Non-
steroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-2
can prevent certain, but not all, cancers [7]; and some NSAIDs,
such as sulindac sulfone, act independently of COX and
prostaglandin E2 (PGE2) inhibition [8]. Other NSAIDs, e.g.
celecoxib, can paradoxically enhance tumor progression in
APC
Min/+ mice, which model intestinal tumorigenesis [9]. While
COX-2 and its metabolite PGE2 are undoubtedly important,
para-inflammation may enhance tumorigenesis by mechanisms
that are incompletely understood. Innate immune mechanisms are
prime candidates for investigation.
Usually, innate immune inflammation consists of a ‘‘wounding’’
phase to annihilate pathogens, and a ‘‘healing’’ phase to repair
and regenerate damaged host tissue [10]. The transition between
phases depends on gradual exhaustion of inflammatory mediators
and conversion of certain pro-inflammatory mediators, e.g. PGD2,
into anti-inflammatory metabolites, D12-PGJ2 [11,12,13]. Ele-
ments of the inflamed site itself, e.g. reactive oxygen species (ROS),
albumin, fibroblasts and neutrophils, orchestrate this conversion
[14,15,16,17]. For example, reactive oxygen species (ROS) cause
non-enzymatic peroxidation of essential fatty acids, like arachi-
donic acid (AA) [18]. AA hydroperoxides transform readily into
reactive products containing an a,b–unsaturated carbonyl [19,20]
that include acrolein (2-propenal) [21,22], 4-hydroxy-2-nonenal
(4-HNE) [23], and cyclopentenone prostaglandins (cyPGs), PGA2
and D12-PGJ2 [24]. Covalent modification of NFkB and IKKa/b
proteins by these a, ß–unsaturated carbonyl metabolites (i.e.
protein alkylation) seems to be a ‘‘switch’’ to terminate
inflammation [25]. Following this precedent, we hypothesized
that alkylation may also act as a ‘‘switch’’ to initiate repair and
regeneration of tissue damaged by inflammation.
PTEN (phosphatase tensin homolog on chromosome 10) is a
phosphoinositide-3-phosphatase with two physiological roles:
tumor suppressor and regulator of anabolic/catabolic cell
signaling. The PTEN gene is frequently mutated or inactivated
in advanced cancers [26]. Using MCF7 and HEK-293 cells, we
report that reactive a, ß–unsaturated carbonyls (acrolein, 4-HNE,
and D12-PGJ2) inactivate the PTEN protein – not the gene - by
alkylation. Inactivation of PTEN by a, ß–unsaturated carbonyls
leads to increased Akt signaling, enhanced nuclear b-catenin
signaling, and augmented cellular proliferation. Redox signaling
by PTEN may have evolved to enable cells (tissues) to stratify their
response to oxidative stress. For example, transient inhibition of
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13545PTEN by reactive oxygen or carbonyl species, and the
corresponding signaling through Akt/GSK3b/b-catenin/TCF4/
Lef1 might benefit the host via increasing proliferation and
regeneration of tissue damaged by acute inflammation or oxidative
stress. Errant and persistent PTEN inactivation by the same
molecular mechanism might favor tumor progression and provide
an etiological link between ‘smouldering’ inflammation and
certain cancers, especially colorectal cancer, where both the
PTEN and the APC tumor suppressors restrict nuclear b-catenin
signaling [27].
Results
The a, ß–unsaturated carbonyls acrolein, 4-HNE and D12-
PGJ2 covalently modify cellular PTEN
We exposed MCF-7 cells to representative a, ß–unsaturated
carbonyl (Figure 1C)o rH 2O2, then selectively tagged any
proteins that had oxidized or carbonylated thiols using NEM-
biotin (Figure 1A). We then sequestered proteins with a biotin
epitope onto NeutrAvidin (NA) beads and identified carbonylated
PTEN by SDS-PAGE and immunoblotting. MCF-7 cells treated
with 10 mM D12-PGJ2, 4-HNE, or acrolein contained carbony-
lated PTEN in amounts comparable to cells treated with 100 mM
H2O2 (Figure 1A, NA pulldown). This method does not
distinguish between oxidized and carbonylated thiols on PTEN.
However, electrophoresis under non-reducing conditions, followed
by western blotting, showed that PTEN migrated as a discrete
isoform due to an oxidized disulfide [28,29], which occurred only
in cells treated with 100 mMH 2O2, but not in cells treated with a,
ß–unsaturated carbonyl (D12-PGJ2, 4-HNE, acrolein) or 15-
HpETE, a lipid hydroperoxide (Figure 1B).
Cyclopenteneone PG-biotin analogs are model a,
b–enones that alkylate PTEN
The cysteinyl thiolate in the PTEN active site (–HC(X5)RT–) is
prone to oxidation because it is a strong nucleophile, pKa ,5.
Figure 1. a, ß–unsaturated carbonyls covalently modify cellular PTEN. (A) Diagram of the procedure to identify PTEN with an oxidized or
alkylated thiol in cells exposed to ROS or a, ß–unsaturated carbonyls. The anti-PTEN immunoblot shows oxidized or carbonylated PTEN (NA Pulldown)
relative to total PTEN (Cell Lysate) isolated from MCF-7 cells treated 30 min with vehicle (DMSO), 10 mM D12-PGJ2 or 4-HNE versus 10 min with
100 mMH 2O2; an immunoblot from a separate experiment shows oxidized, carbonylated and total PTEN in cells treated for 30 min with vehicle or
20 mM acrolein versus 10 min with 100 mMH 2O2.( B) Anti-PTEN immunoblot of MCF-7 cell lysates fractionated by SDS-PAGE under non-reducing
conditions. PTEN oxidized to a Cys
124-Cys
71 disulfide appears as a faster migrating species (PTEN oxidized disulfide) only in cells treated with H2O2.
This species was undetectable in MCF-7cells treated 30 min with DMSO vehicle or 20 mM each D12-PGJ2, 4-HNE, acrolein or 15-HpETE. (C) Chemical
structures of typical a, ß–unsaturated carbonyls. Acrolein and 4-HNE are a, b enals; D12PGJ2 is an a,b enone. Electrophilic b carbons are denoted with
d
+. Blots are representative of results obtained in at least three independent experiments.
doi:10.1371/journal.pone.0013545.g001
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unsaturated carbonyls. We used CyPG-biotin analogs, which have
an electrophilic b-carbon capable of nucleophilic addition
(Michael reaction), as chemical models to test this hypothesis
[30]. Alkylation of any cellular proteins by these analogs would
introduce a biotin epitope de novo (Figure 2A). PGA1-biotin and
D12 PGJ2-biotin were both taken up into MCF-7 cells and formed
covalent adducts with ,20 proteins (Figure 2B). D12 PGJ2-biotin
(a bi-functional dienone) was more reactive than PGA1-biotin
(mono-functional enone), agreeing with others who reported ,20-
30 protein targets modified by cyPG-biotin in 3T3 cells or
mitochondria [31,32]. Sequestration of de novo biotinylated cellular
proteins on NA beads, followed by immunoblot with anti-PTEN
antibodies, showed that PTEN formed a covalent adduct ,10-fold
more readily with D12-PGJ2-biotin than with PGA1biotin
(Figure 2C, lane 4 vs lane 3).
The a, ß–enone, D12-PGJ2, interferes with PTEN
suppression of Akt kinase
Growth factors, insulin, and other stimuli prompt PI3-K to make
PIP3, which recruits PKB/Akt kinase to the cell membrane where
PDK1/2 phosphorylates Akt Thr
308 and Akt Ser
473 residues,
respectively [33,34,35]. PTEN down-regulates PKB/Akt activation
by metabolizing PIP3 to PIP2 [36]. a, ß–unsaturated carbonyls that
alkylate cellular PTEN may interfere with its suppression of Akt
kinase. A representative a,ß – e n o n e ,D12-PGJ2, caused a concen-
tration and time dependent increase in phospho-(T
308) Akt in MCF-
7c e l l s .A sl i t t l ea s,2 mMD12-PGJ2 causedahalf-maximal response
(Figure3A).Increasesincellularphospho-(T
308)Aktweredetectable
at 10 min, maximal at 30 min, and durable for .120 min
(Figure 3B). D12-PGJ2 increased formation of phospho-(T
308)Akt
without altering formation of phospho-(S
241)PDK1 (the kinase that
phosphorylates T
308 of Akt), and without altering PTEN protein
Figure 2. CyPG biotin analogs: model a, ß–unsaturated carbonyls alkylate cellular PTEN. (A) Michael addition reaction between PTEN and
a D12-PGJ2-biotin analog. Following treatment of cells with cyPG-biotin, proteins with a de novo biotin epitope were sequestered onto neutravidin
beads (NA Pulldown), then fractionated by SDS-PAGE for immunoblotting. (B) Anti-biotin immunoblot of proteins from lysates of MCF-7 cells treated
with DMSO (lane 1), 10 mM PGA1-biotin (lane 2), and 10 mM D12PGJ2-biotin (lane 3). D12-PGJ2 biotin formed a covalent adduct with proteins more
readily than PGA1-biotin (arrowheads). (C) Anti-PTEN immunoblot of cellular PTEN that formed a covalent adduct with cyPG-biotin (NA Pulldown)
relative to total PTEN (Cell Lysate) from MCF-7 cells treated with DMSO (lane 1), 1 or 10 mM PGA1-biotin (lanes 2, 3), and 1 or 10 mM PGJ2-biotin (lanes
4, 5). Blots are representative of results obtained in at least three independent experiments.
doi:10.1371/journal.pone.0013545.g002
Electrophiles Inactivate PTEN
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13545expression (Figure 3C). These data suggest that D12-PGJ2
interfered with PTEN’s capacity to restrain activation of Akt kinase.
Consistent with this interpretation, co-treatment of cells with cyPGs
plus 50 mM LY294002, lowered levels of phospho-(T
308)Akt by
inhibiting PI3-K, at the apex of the PI3-K/RPDK1/2RAkt kinase
cascade(Figure3C,lanes3vs2,and6vs.5).Furthermore,1 mMo f
various PGA and PGJ isomers, and other a, ß–enones directly
inhibited isolated PTEN enzyme [Table 1]. The electrophilic b
carbonofcyPGsisessentialforinhibition,sinceastructurallysimilar,
but non-electrophilic cyPG, PGB1, was inactive.
Structure-activity experiments showed that various J-series cyPGs,
including PGJ2, D12 PGJ2 and 15-deoxy- D12, 14-PGJ2,i n c r e a s e d
phospho-(T
308)Akt in MCF-7 cells, compared to vehicle or their
precursor PGD2 (Figure 3D). PGA1 had a modest effect on cellular
Akt phosphorylation (Figure 3C, lane 5), which corresponds with its
weaker covalent modification of cellular PTEN (Figure 2C, lane 3).
Activated phospho-(T
308/S
473)Akt kinase can phosphorylate
different protein substrates that regulate cell proliferation and fate
Figure 3. The a, ß–unsaturated enone D12PGJ2 interferes with PTEN suppression of Akt activation. (A) Immunoblots of phospho-
(T
308)Akt relative to total Akt in lysates from MCF-7 cells treated 30 min with 0–20 mM D12-PGJ2. The bar graph shows the increase in phospho-
(T
308)Akt/total Akt (mean 6 s.e.m) from n$3 separate experiments. (B) Immunoblot of phospho-(T
308)Akt relative to total Akt in lysates from MCF-7
cells treated with 20 mM D12-PGJ2 for 0–120 min. The bar graph shows the increase in phospho-(T
308)Akt/total Akt (mean 6 s.e.m) from n=4
separate experiments. (C) Immunoblots of total Akt, phospho-(T
308)Akt, PTEN, phospho-(S
241)PDK1 from lysates of MCF-7 cells treated 30 min with
20 mM D12-PGJ2 (lane 2, 3) and 20 mM PGA1 (lane 5, 6) in the presence of the PI3-K inhibitor 50 mM Ly294002 (lane 3, 6) or DMSO vehicle (lane 2, 5).
(D) Immunoblot of phospho-(T
308)Akt relative to total Akt in lysates from MCF-7 cells treated 4 hrs with vehicle, the cyclopentenones - PGJ2, D12-
PGJ2, and 15-deoxy-D12-PGJ2, or their precursor PGD2. For (C) and (D), blots are representative of results obtained in three independent experiments.
doi:10.1371/journal.pone.0013545.g003
Table 1.
Test Compound PTEN Activity
% Inhibition
Vehicle 0
10 mM PGB1 562
1 mM PGA1 3765
1 mM PGA2 4063
1 mM PGJ2 4865
1 mM D12-PGJ2 5664
1 mM 15-deoxy-D12, D12-PGJ2 7363
10 mM Acrolein 4066
10 mM 4-hydroxy-2-nonenal 5762
Mean 6 sem, n=3.
doi:10.1371/journal.pone.0013545.t001
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S/T epitope, coincided with increased phospho-(T
308)Akt in
MCF-7 cells treated with 10 mM D12-PGJ2 (Figure 4A). Akt
kinase activation also coincided with Akt-dependent proliferation
in MCF-7 cells treated with 1–10 mM D12-PGJ2 (Figure 4B).
This finding is consistent with reported bi-phasic actions of cyPGs,
whereby they increase proliferation of cultured cells at ,1 mM
[37,38], while they decrease proliferation or cause apoptosis by
modifying other protein targets at ,50 mM [39].
a, ß–unsaturated carbonyls cause a time-dependent
accumulation of cellular phospho-(S
473)Akt kinase
(active) R phospho-(S
9)GSK3b (inactive) R b-catenin
and a rise in nuclear b-catenin signaling
GSK3b converts b-catenin to phospho-(S
33/37/T
41) b-catenin,
which is rapidly eliminated by the 26S proteasome [40]. GSK3b
acts in concert with the tumor suppressor APC. In cells with
mutant APC, or when WNT ligands stimulate cells with wild type
APC, GSK3b fails to phosphorylate b-catenin, which allows it to
accumulate, associate with other nuclear transcription factors and
express its target genes (e.g. c-myc, cyclin D1) [41]. PTEN can block
b-catenin accumulation/signaling by favoring retention of active
GSK3b and inactive PKB/Akt kinase in some [42,43], but not all
experimental systems [44,45]. Accordingly, inactivated PTEN
should augment b-catenin signaling by favoring retention of
inactive phospho-(S
9)GSK3b and active phospho-(S
473) Akt
kinase. We thus hypothesized that these electrophilic mediators
may affect ß-Catenin signaling through this mechanism. To
investigate this further, we used HEK 293 cells which have an
intact ß-Catenin signaling pathway. We found that the different a,
ß–unsaturated carbonyls that alkylated PTEN (6 mM D12 PGJ2,
6 mM 4-HNE and 20 mM acrolein) all caused a time-dependent
rise in phospho-(S
473)Akt (i.e. active Akt kinase), with a
Figure 4. a, ß–unsaturated carbonyls interferes with Akt kinase and downstream signaling in MCF7 and HEK 293 cells. (A)
Immunoblots of phospho-(T
308)Akt, total Akt, and several phosphoproteins with (K/R)-x-(K/R)-xx-(S/T), a motif recognized and phosphorylated by
active phospho-(T
308)Akt, in lysates from MCF-7 cells treated 0 and 10 mM D12-PGJ2.( B) Relative proliferation of MCF-7 cells (mean 6 s.e.m, n=4)
treated with 0, 1, and 10 mM D12-PGJ2 alone (&), or in the presence of 10 mM of inhibitor IV (&), an Akt kinase inhibitor. (C) Immunoblots of
phospho-(S
473)Akt, total Akt; phospho(S
9)GSK3b, total GSK3b; and b-catenin and tubulin in lysates from HEK 293 cells after treatment for 0,1, 3, 6 and
16 hrs with 6 mM D12PGJ2,6mM 4-HNE or 20 mM acrolein. For (A) and (C), blots are representative of results obtained in three independent
experiments.
doi:10.1371/journal.pone.0013545.g004
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9)GSK3b (i.e. inactive GSK3b)
and b-catenin (Figure 4C). To determine if a, b–unsaturated
carbonyls enhanced nuclear b-catenin signaling, we used HEK
293 cells engineered to stably express WNT3A and Super-
TopFlash (STF) reporter gene [46]. These cells, called STF3A
cells, thus secret WNT3A, an autocrine/paracrine stimulus for
FZD receptors that slows APC-dependent degradation of b-
catenin (Figure 5A). Nuclear b-catenin signaling in STF3A cells is
Figure 5. a, ß–unsaturated carbonyls enhance nuclear b-catenin signaling in STF3A cells: structure activity relationships. (A) STF3A
cells harbor a stably integrated transgene which expresses WNT3A (1). When secreted, WNT3A elicits autocrine/paracrine stimulation of Fzl receptors
(2) which inhibits APC-dependent turnover of b-catenin (3). If b-catenin is not phosphorylated by GSK3b, it can accumulate as a b-catenin:LEF dimer
(4) and bind to promoters on stably integrated b-catenin:luciferase reporter gene (SuperTop Flash) (5). Luciferase activity in cell lysates is
proportional to nuclear b-catenin signaling. (B) Nuclear b-catenin signaling (luciferase luminescence) in STF3A cells (2610
4 cells/well) grown for
24 hrs in medium containing 0, 10, or 30 ng/ml of DKK1 (mean + s.d., n=3). DKK1, a wnt antagonist, inhibited b-catenin signaling (C) Nuclear b-
catenin signaling in STF3A cells (2610
4 cells/well) grown for 24 hrs in medium containing 20 mM of cyPGs; a,b-enals or primary PGs. Several reactive
electrophiles enhanced b-catenin signaling by ,2–4 fold. Histogram represents the mean + s.e.m., n=4.
doi:10.1371/journal.pone.0013545.g005
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responsive to DKK1, a WNT antagonist that inhibited b-catenin
signaling in STF3A cells in a concentration-dependent manner
(Figure 5B).
Several reative carbonyl metabolites, each with an electrophilic
a,b enone or enal substituent, enhanced expression of the b-
catenin:luciferase reporter gene in STF3A cells (Figure 5C).
Luciferase reporter activity rose by ,4-fold over baseline (p,0.01)
in STF3A cells incubated with D12 PGJ2 or 4-HNE; by ,3-fold
(p,0.01) in cells with other PGJ analogs, acrolein or 4-ONE; and
by ,1.5-fold (p,0.05) in cells with PGA2. Consistent with our
mechanistic hypothesis, neither PGB2 nor MDA had a detectable
effect. PGB2 is a cyPG, but tautomerism prevents the charge de-
localization required to create an electrophilic b carbon, which is
required for protein alkylation. MDA (b-hydroxy-acrolein) pene-
trates cell membranes poorly because it is .99% ionized at
physiological pH ,7.4 used in our experiments. Neither PGE2
nor other primary PG metabolites of COX-1 or -2 had any effect
on nuclear b-catenin signaling in STF3A cells. We draw attention
to the fact that ectopic over-expression of EP receptors in HEK
293 cells was required to elicit any PGE2 mediated b-catenin
signaling [47]. The weak response to PGE2 and other PG’s in
Figure 5C may reflect the constitutive levels of EP, FP, DP or IP
receptors in STF3A cells or rapid metabolism of PGs, or both.
Enhanced b-catenin signaling in STF3A cells was concentration
dependent between 2–20 mM for acrolein, 4-HNE and D12 PGJ2
(Figure 6A). Depletion of cellular GSH to ,10% of baseline by
treatment with 100 mM BSO potentiated b-catenin signaling, e.g.
in STF3A cells treated with 2 and 6 mM D12 PGJ2 (Figure 6B).
This is consistent with the role of reduced glutathione in the
conjugation of reactive metabolites, and protection of redox
sensitive proteins from alkylation [20].
Discussion
The PTEN tumor suppressor gene is frequently mutated or
inactivated in advanced cancers [26,48]. PTEN is a phosphoino-
sitide-3-phosphatase that metabolizes PIP3 to PIP2 [36], thereby
Figure 6. a, ß–unsaturated carbonyls enhance nuclear b-catenin signaling in STF3A cells:concentration-response relationships. (A)
Nuclear b-catenin signaling (luciferase luminescence) in STF3A cells (2610
4 cells/well) grown for 24 hrs in medium containing 0, 2, 6 and 20 mM each
of acrolein (%), D12 PGJ2 (&) and 4-HNE (&). (B) Nuclear b-catenin signaling in STF3A cells (2610
4 cells/well) grown for 24 hrs in medium containing
0, 2 or 6 mMo fD12 PGJ2 alone (&)o rD12 PGJ2 plus 100 mM BSO. GSH levels fell by 79% and 88% at 6 and 24 hrs after treating cells with BSO; 92–
95% of cells were still viable at 24 hrs. Bars represent the mean 6 s.e.m from n$3 separate experiments.
doi:10.1371/journal.pone.0013545.g006
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oncogene that controls anabolic growth and specification of cell
fate [33,34,35]. PTEN, itself, is regulated post-translationally by
phosphorylation [49], acetylation [50], and reversible oxidation of
its catalytic cysteine
124 residue [28,29]. Oxidation of cellular
PTEN can involve H2O2 derived from NADPH oxidase [51],
superoxide dismutase [52], or enzymatic peroxidation of arachi-
donic acid (AA) by COX-1, COX-2 or 5-LOX [53]. All of these
enzymes are commonly over-expressed and activated by inflam-
mation or neoplastic transformation. PTEN oxidation, and any
attendant pathophysiology, varies with the degree of cellular
exposure to reactive oxygen species (ROS). In these studies, we
demonstrate that the chemistry which facilitates oxidation of
PTEN can also facilitate its alkylation by electrophilic a, ß-enals
and a, b-enones [19,20].
PTEN epitomizes the adaptation of redox-responsive thiols for
cell signaling, as well as their potential vulnerability to by-products
of oxidative stress and inflammation. PTEN is inactivated by two
distinctive redox-mediated processes: 1) intra- or inter-molecular
disulfide formation by ROS and 2) thiolate carbonylation (Michael
addition) by electrophilic a, ß–unsaturated carbonyls (Figure 1–3).
Hydrogen peroxide (H2O2), a prototypical ROS, inhibits cellular
PTEN by directly oxidizing its catalytic Cys
124 to a sulfenic acid
intermediate, which then forms an inactive, intra-molecular
Cys
124–71 disulfide [28,29]. Our data show that several represen-
tative, electrophilic carbonyl species (a,ß-enals and a,ß-enones),
which can occur endogenously as byproducts of lipid peroxidation
during inflammation or oxidative stress, alkylate and inactivate
PTEN. Inactivation of PTEN by redox-mediated processes causes
an increase in activity of the proto-oncogene Akt. Hyperactivation
of Akt increases proliferation and survival of many different
cancers.
Signaling by H2O2 spans a wide pathophysiological continuum
[54] and a comparable role for reactive electrophiles seems
plausible. Reactive carbonyl species such as acrolein, 4-HNE and
D12PGJ2 represent a sub-set of electrophiles commonly produced
during oxidative stress and inflammation. These findings might
extrapolate to electrophilic agents lacking a carbonyl but
containing other electron withdrawing groups, and we refer to
them generally as ‘‘reactive electrophiles’’. First, like H2O2,
reactive electrophiles occur in vivo during inflammation and
oxidative stress [16,18,19,22]. Second, reactive electrophiles
covalently modulate other proteins that regulate important
signaling processes; i.e. LKB1/STK11 [55], NFkB [56], and
IKKb. Third, H2O2 and reactive electrophiles both originate from
a combination of spontaneous and enzymatic processes, which
often coincide in inflamed tissues [57]. H2O2 derives from
superoxide anion, O2
2, the primary metabolite of NADPH
oxidases. Spontaneous and enzymatic dismutation converts O2
2
into H2O2. Likewise, spontaneous and enzymatic lipid peroxida-
tion generates acrolein and 4-HNE [18,57]. cyPGs originate from
the lipid endoperoxide PGH2, the primary metabolite of COX-1
and -2. Enzymatic and spontaneous scission of endoperoxide
bonds converts PGH2 into PGE2 and PGD2; albumin/serum then
causes their dehydration into PGA2, PGJ2, and their isomers
[14,16,24].
While speculative, it appears that ROS and reactive electro-
philes (H2O2, acrolein, 4-HNE, D12 PGJ2) may have both evolved
to play disparate roles in innate immunity: 1) annihilating
pathogens and 2) resolving inflammation. Analogous to inactiva-
tion of NFkB and IKKab, temporary inactivation of the PTEN
tumor suppressor protein by its alkylation, and attendant
activation of PKB/Akt kinase proto-oncogenes, might help
normalize morphology and histology at acutely inflamed tissues
by releasing their restriction on cell proliferation, anabolic growth
and fate specification [34,35]. In ordinary situations repair and
resolution should help terminate innate immune inflammation
(Figure 7,a). However, this mechanism might also confer
inescapable risks if PTEN were inactivated errantly or persistently.
Furthermore, reactive electrophiles also inactivate other notable
tumor suppressors, including p53 [30] and LKB1/STK11 [55].
This combined and sustained inactivation of tumor suppressors
could contribute significantly to inflammation-associated tumori-
genesis and subsequently prolong the cycle of tumor-associated
para-inflammation (Figure 7,b). Overall, our data and model
align with the observation that tumors are wounds that fail to heal
[58]. In this situation, tumor progression may derive partly from
mal-adaptation of a molecular mechanism that evolved to
terminate and resolve innate immune inflammation.
Inflammation is a critical component of tumor progression.
Many cancers arise from sites of infection, chronic irritation and
inflammation. The tumor microenvironment, which is comprised
largely of inflammatory cells, plays a major role in the neoplastic
process, fostering proliferation, survival, and migration. We show
herein that reactive carbonyl species that are commonly produced
during inflammation covalently modify and inactivate PTEN
tumor suppressor. Importantly, the mechanism we describe might
also extrapolate to: 1) other electrophilic species generated by
inflammation, oxidative or xenobiotic stress (i.e. other a,ß
unsaturated aldehydes and ketones; allylic or vinyl epoxides;
quinones, chlorhydrins, chloramines, vinyl sulfones; and 2) other
members of the PTP superfamily that are redox sensitive. These
studies extend our understanding of the mechanisms by which
inflammation contributes to the initiation and progression of
cancer.
Materials and Methods
Materials
We used minimum essential medium (MEM), supplements,
bovine insulin, gentamicin, human embryonic kidney HEK-293
cells, and HEK-293 cells containing the Epstein Barr virus nuclear
antigen 1 gene (HEK-EBNA1) (Invitrogen; Carlsbad, CA); MCF-7
cells (HTB-22, American Type Culture Collection; Manassas,
VA); PGs, cyPG-biotin analogs, and WST proliferation assay kits
(#10008883) (Cayman Chemical; Ann Arbor, MI); Complete
TM
protease inhibitor mixture (Roche Molecular Biochemicals;
Indianapolis, IN); lysis buffer 0.6% Igepal CA-630 in PBS
(Promega; Madison, WI); NeutrAvidin conjugated beads, NEM-
biotin and goat anti-biotin polyclonal antibodies (#31852) (Pierce
Chemical; Rockford, IL); a PI3-K inhibitor, LY294002 (# 9901),
polyclonal antibodies against PTEN (#9552), Akt (#9271),
phospho-(Thr
308)Akt (#9375), phospho-(S
473)Akt (#9271), phos-
pho-(S
9)GSK3b (#9336), GSK-3b (# 9332), phospho-(Ser
33/37/
Thr
41) b catenin (#9561S) K/R-x-K/R-x-x-S/T(PO4) epitopes
(#9614) and phospho-(S
241)PDK1 (#3061) (Cell Signaling
Technologies; Danvers, MA); b-catenin (# C19220)(BD Trans-
duction Laboratories; Franklin Lakes, NJ); HRP (horseradish
peroxidase) conjugated secondary antibodies (Santa Cruz Bio-
technology; Santa Cruz, CA); polyvinylidene difluoride (PVDF)
membranes and Western Lightning
TM chemiluminescence re-
agents (Perkin-Elmer; Waltham, MA); PTEN enzyme assay kits (#
17–351)(Upstate Biotechnology; Lake Placid, NY); Akt inhibitor
IV (#124011) (Calbiochem; San Diego, CA); acrolein (#01680),
crotonaldehyde (# 262668), L-Buthionine-sulfoximine (BSO)
(B2515), H2O2 30% solution (H-1009), malondialdehyde (Fluka
Cat.# 63287) (Sigma-Aldrich; St Louis, MO); DKK-1 (#1096-
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(Cat.# 10101-2) (Biotium Inc., Hayward, CA).
Cell culture
MCF-7 breast cancer cells (ATCC) were grown in MEM with
10% v/v FBS, 2 mM L-glutamine, 1.5 g/l NaHCO3, 0.1 mM
non-essential amino acids, 1 mM sodium pyruvate, 0.01 mg/ml
bovine insulin, and 0.01 mg/ml gentamicin. HEK-293 cells
(ATCC) were grown in MEM with 10% fetal calf serum, 100
units of penicillin/streptomycin, 2 mM L-glutamine, and 1 mM
pyruvate.
Identification of modified PTEN by tagging with biotin-
conjugated maleimide
MCF-7 cells (MEM 1% v/v FBS) were treated for 30 min with
vehicle, or reactive electrophiles (10 mM D12-PGJ2, 4-HNE,
acrolein), or 100 mMH 2O2. Media was removed; cells were
frozen at 280uC for 15 min; transferred to vacuum and incubated
1h , 2 5 uC with 1 ml of O2-free extraction buffer (50 mM
NaHPO4, pH 7.0, 1 mM EDTA, 10 mM NEM [N-ethyl
maleimide], 10 mM IAA [iodoacetic acid], 1% Triton X-100,
5 mM NaF, 50 mg/ml leupeptin and 50 mg/ml aprotinin). This
treatment selectively alkylates all reduced thiols in PTEN, but not
oxidized thiols or thiols modified by Michael addition with
reactive electrophiles. Samples were washed in 1 ml of O2-free
extraction buffer then transferred to a 15-ml conical tube. After
adding SDS to a final concentration of 1% v/v, the mixture was
held 2 h at 25uC in the dark, and proteins were precipitated with
TCA [trichloroacetic acid], 10% v/v for 1 h. The precipitate was
washed twice with acetone to remove traces of TCA, NEM, and
IAA. Precipitated proteins were solubilized and oxidized or
modified cys residues were reduced in 0.1 ml of O2-free reducing
buffer (50 mM Hepes-NaOH, pH 7.7, 1 mM EDTA, 2% SDS
and 4 mM DTT) for 30 min at 50uC. Reduced proteins were
subsequently biotinylated with 0.9 ml of a solution containing
50 mM NaHPO4 pH 7.0, 1 mM EDTA, and 1 mM biotin
conjugated to polyethylene oxide-maleimide for 30 min at 50uC.
Proteins were precipitated in 10% v/v TCA for 1 h. The
precipitate was isolated by centrifugation, washed with dry ice-
chilled acetone, and solubilized in 0.3 ml of 50 mM Hepes-
NaOH, pH 7.7, 1 mM EDTA, and 2% SDS. The sample was
then diluted with 0.3 ml of the same solution without SDS. 15 mg
protein was assayed by immunoblot for PTEN. A separate sample
(200 mg protein) was added to 100 mL immobilized NA beads in
1 ml PBS, 0.4% v/v Tween 20. This suspension was rotated 16 hr
at 4u, centrifuged, and beads were washed twice with PBS/0.4%
v/v Tween 20. Loading buffer (50 mL) with 5% BME was added
directly to beads, boiled for 10 min to release maleimido-
biotinylated proteins, and 20 mL was assayed by immunoblot for
total and oxidized PTEN.
Identification of PTEN occurring as an intra-molecular
disulfide
MCF-7 cells (MEM 1% v/v FBS) treated for 30 min with
20 mM D12-PGJ2, 4-HNE, acrolein, 15-HpETE or for 10 min
Figure 7. Model Depicting Hypothetical Roles of PTEN Alkylation in Inflammation and Cancer.
doi:10.1371/journal.pone.0013545.g007
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were fractionated by non-reducing SDS-10% PAGE, followed by
anti-PTEN immunoblot to distinguish native PTEN from oxidized
PTEN occurring as an intra-molecular Cys
124-Cys
71 disulfide [28].
Identification of PTEN covalently modified by
cyclopentenone PG-biotin analogs
MCF-7 cells (MEM 1% v/v FBS) treated 1 hr with 1–10 mMo f
the aminopentylbiotinamide analogs of PGA1 or D12 PGJ2, were
lysed, sonicated 106for 1 s at 4uC, then centrifuged 10,0006g for
10 min. Supernatant with 100 mg of protein was incubated with
100 ml of NA beads in 1 ml PBS with 0.4% Tween 20 for 16 h at
4uC to sequester proteins containing a biotin epitope introduced de
novo by reaction with cyPG-biotin analogs. The beads were then
centrifuged at 5006 g for 5 min to isolate neutravidin-biotin
complexes (NA pulldown). The beads were washed 36with 1 ml
of PBS/0.4%Tween 20 then boiled 5 min in Laemmli loading
buffer with 5% BME to release bound proteins. These samples
were analyzed by immunoblotting for PTEN or proteins with a
biotin epitope.
Western immunoblotting
Following treatment with reactive electrophiles, H2O2,o r
enzyme inhibitors, MCF-7 or HEK-EBNA cells were lysed in
250 mM sucrose, 50 mM Tris pH 7.4, 5 mM MgCl2,1 m M
EGTA, 16 Complete
TM protease inhibitor, 2 mM NaF and
2 mM sodium orthovanadate. Samples were dissolved in 50 mlo f
Laemmli loading buffer, 0.5% BME and heated at 95uC for
10 min. Samples (15–30 mg protein) were fractionated by SDS-
PAGE and transferred to PVDF membranes. Membranes were
blocked with 5% w/v nonfat dry milk in TBS-T, then incubated
for 16 h at 4uC with primary antibodies directed against PTEN
(1:1000), biotin (1:10,000), Akt (1:1000), phospho-(T
308)Akt
(1:1000), phospho-(S
473)Akt (1:1000), phospho-(S
241)PDK1
(1:1000), GSK3b (1:1000), phospho-(S
9)-GSK3b (1:1000),
RxRxx-phospho-(S/T) (1:1000) or b-catenin (1:1000) followed
by HRP-conjugated secondary antibody (1:5000). Antigen-anti-
body complexes were detected with Western Lightning
TM ECL
reagents. The intensity of chemiluminescent protein-antibody
complexes was quantified with a Kodak Image Station 440
TM. Bar
graphs depict the mean 6 S.E. from densitometric analyses of
separate experiments.
Akt phosphorylation and signaling
,1610
6 MCF-7 cells (MEM 1% v/v FBS) were treated with 0–
20 mM D12-PGJ2 for 30 min at 37uC, or with 20 mM D12-PGJ2
for 0–120 min to determine concentration and time dependence.
,1610
6 MCF-7 cells were also treated 30 min at 37uC with
10 mM of various PGs, including PGD2 and its cyPG dehydration
products PGJ2, D12-PGJ2 and 15-deoxy-D12, D14-PGJ2; PGE2
and its cyPG dehydration products PGA2, its epimer 8-iso-PGA2,
and its isomer PGB2 to determine structure-activity relationships.
In certain experiments cells were also treated with 50 mM
LY294002, 5 mM troglitazone, or 10 mM Akt inhibitor IV. Lysates
from treated cells (15 mg protein) were fractionated on SDS-10%
PAGE and proteins were transferred to PVDF membranes for
immunoblot analysis of Akt, phospho-(T
308)Akt, phospho-
(S
473)Akt, Akt substrate proteins containing the K/R-x-K/R-x-x-
S/T(PO4) epitope, phospho-(S
241)PDK1, and PTEN.
Wnt/b-catenin signaling in STF3A cells
STF cells are HEK-293 cells containing a stably integrated
SuperTopFlash (STF) transgene with TCF binding sites upstream
of a luciferase reporter gene [59]. STF cells have negligible b-
catenin/TCF-LEF transactivation and luciferase expression unless
they are exposed to a Wnt ligand, e.g. WNT3A. We derived a
subsidiary cell line, designated STF3A, by transfecting parental
STF cells with a linearized pPGK + Wnt3A plasmid and a
linearized blasticidin resistance plasmid for cell selection. STF cells
grown on 10-cm plates were transfected using LipofectAMINE
2000 (Invitrogen). At 24 h after transfection, cells were serially
diluted, re-plated and grown in medium with blasticidin (10 mg/
ml) for 14 d. Forty colonies were screened for b-catenin/TCF-LEF
activity by measuring luciferase activity normalized to total protein
concentration. The selected STF3A clones, which stably expressed
and secreted WNT3A, were maintained at 37uC in DMEM with
10% FBS, penicillin/streptomycin and 10 mg/ml blasticidin in a
humidified incubator with 5% CO2. We measured wnt/b-catenin
signaling in STF3A cells by quantifying their Super TopflashH
luciferase reporter signal. STF3A cells (20,000/well) were plated in
white, clear bottom 96-well plates coated with poly-L-lysine and
grown 24 h at 37uC. Medium was removed and replaced with
200 ml fresh medium containing 0–300 ng/ml DKK1; 2–20 mM
of a,b-enone containing cyPGs; 2–20 mMo fa,b-enal metabolites
derived from lipid peroxidation (acrolein, MDA, crotonaldehyde,
4-HNE, 4-ONE); 20 mM of primary PGs, PGH2, PGE2, PGF2a,
PGD2, PGI2;2 0mM BSO, a glutathione synthesis inhibitor; other
inhibitors, or DMSO vehicle. STF3A cells were incubated for 24 h
at 37uC, washed with 200 ml PBS at 4uC, and lysed with 20 ml lysis
buffer. Luciferin (60 ml/well) was added and luciferase activity in
the lysates was quantified by fluorimetry. LDH activity in the
lysate, an index of cell count, was quantified by spectroscopy. The
ratio of luciferase/LDH activity is proportional to nuclear b-
catenin signaling in STF3A cells.
Inhibition of PTEN Enzymatic Activity
Inhibition of PTEN with 0–30 mM reactive electrophiles was
quantified by using a PTEN enzyme assay kit (# 17–351, Upstate
Biotechnology).
Statistical analysis
Statistical significance at p,0.05 was assessed by analysis of
variance (ANOVA) with Bonferroni’s post-hoc test for compari-
sons among groups.
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